Greenwich LifeSciences at SABCS 2026
Dec 8–11, 2026 San Antonio, TX ~11k attendees Website
Greenwich LifeSciences brings 2 presentations to SABCS 2026 in San Antonio, and exhibits at Booth 809. The biotech presents its phase 3 trial of GLSI-100 (GP2 with GM-CSF) and early efficacy and safety results from the trial's arm for patients without HLA-A*02.
| Organization | SABCS 2026 Attendance |
|---|---|
Greenwich LifeSciences Stafford, TX | |
Clinical-stage biotech testing GP2, a HER2 peptide immunotherapy, in the Phase III Flamingo-01 trial to prevent breast cancer from returning. | Booth Exhibiting at Booth 809 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm |
Find decision makers at Greenwich LifeSciences
Tell us what you sell and we’ll find the people at Greenwich LifeSciences most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with the San Antonio Breast Cancer Symposium, UT Health San Antonio or the American Association for Cancer Research. Organization details are derived from SABCS’s published program and exhibitor list. Submit a correction